DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2003/0232890 A1 Epstein Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2003/0232890 A1 Epstein Et Al US 2003O232890A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0232890 A1 Epstein et al. (43) Pub. Date: Dec. 18, 2003 (54) METHODS FOR TREATING AN (60) Provisional application No. 60/245,323, filed on Nov. IMPAIRMENT IN MEMORY 1, 2000. CONSOLIDATION (30) Foreign Application Priority Data (75) Inventors: Mel H. Epstein, Bristol, RI (US); Kjesten A. Wiig, Providence, RI (US) Oct. 31, 2001 (WO)........................... PCT/US01/45793 Correspondence Address: Publication Classification HAMILTON, BROOK, SMITH & REYNOLDS, P.C. 530 VIRGINA ROAD (51) Int. Cl. ................................................ A61K 31/137 P.O. BOX 91.33 (52) U.S. Cl. .............................................................. 514/649 CONCORD, MA 01742-9133 (US) (73) Assignee: Sention, Inc., Providence, RI (US) (57) ABSTRACT (21) Appl. No.: 10/444,970 Impairments in memory consolidation are treated with an (22) Filed: May 23, 2003 amphetamine compound. In one embodiment, the method includes administering an 1-amphetamine compound. In Related U.S. Application Data another embodiment, the method includes administering an (63) Continuation-in-part of application No. 10/139,606, 1-methamphetamine compound. The method can include filed on May 2, 2002, which is a continuation-in-part determining memory consolidation before, during and/or of application No. 10/003,740, filed on Oct. 31, 2001. after administering the amphetamine compound. Patent Application Publication Dec. 18, 2003. Sheet 1 of 19 US 2003/0232890 A1 Figure 1 a . 2. .9 () Y Saline 0.25 0.5 1,0) 2.0 Dose (mg/kg) Figure 2 400 300 2 5 200 s * 100 O saline S-(+)-amphetamine Group Patent Application Publication Dec. 18, 2003 Sheet 2 of 19 US 2003/0232890 A1 Figure 3 a 9 2 9 A. Saline 2 hr. 1 hr 0.5 hr 0hr Injection Time (hours) Figure 4 400 300 One-way analysis of variance 200 F value - P value summary 2 Are means signif, different? (P & 0.05) 00 Number of groups F R squared Saline 2 hr 1 hr 0.5 hr 0hr Injection Time (Hours) Figure 5 300 2 0 0. 100 s 2 i Patent Application Publication Dec. 18, 2003 Sheet 3 of 19 US 2003/0232890 A1 Figure 6 300 250 15 O Saline S-(+)-amphetamine Patent Application Publication Dec. 18, 2003 Sheet 4 of 19 US 2003/0232890 A1 FIG. 7A FIG. 7B Number of Movements Total Distance so GOO As -o-control 40 -- control 500 --S-(+)-amphetsreic t- --S-(+)-unphetamine 5 400 30 300 20 se C a 200 2 O t) O o 2 4. 6 8 C 0. 2 4. 6 8 0. Time (min) Timc (min) F G. 7 C Number of Rears Movement Tine so 5 a -o-Control -o-contre 4U - --S-(+)-amphetamine -e-S-(+)-amphetamine 3D 3s 0 -- e 20 e lo 2. 0. ( 2 3 4 5 6 7 8 9 2 4 8 8 () Time (min) Time (min) FIG. 7E FIG. 7F Time Spent Resting Number of Stereotyped Movements 15 - 50 -- Control g --d- cott \ 40 --S-(+)-amphetamine -e-S-(+)-amphetamine g pa in 20 4. O 0. --- 0. t 2 4 s 6 8 9 2 4. 6 8 13 Time (min) Time (min) Patent Application Publication Dec. 18, 2003. Sheet 5 of 19 US 2003/0232890 A1 Figure 8 500 34. OO OO 2 O O 100 5 Figure 9 500 34. OO OO 2 O O 100 Saline C105 Patent Application Publication Dec. 18, 2003 Sheet 6 of 19 US 2003/0232890 A1 Figure 10 400 3 O O 200 100 Control C105 Patent Application Publication Dec. 18, 2003 Sheet 7 of 19 US 2003/0232890 A1 Figure 11 300 2 O O 10 O Saline C105 Figure 12 300 2 O O 10 O Saline C105 Patent Application Publication Dec. 18, 2003 Sheet 8 of 19 US 2003/0232890 A1 FIG. 13A Fig. 13B Discrimination Index (D1) - Discrimination Index (D2)- Controls Controls 1. 5 5 0 s x 10 40 30 .9 9 is 20 E 5 t :- 3 10 O 0. Saline ClO5. Saline COS Group Group FIG. 13C FIG. 13D Discrimination Index (D1) - Fornix Discrimination Index (D2) - Fornix Lesion Rats Lesion Rats 5 S 0 4 0. 0 3. O 5 2 () 0. 0 Forlaix + Saline Fornix + C 05 Fornix Saline Fornix + C05 Group Group Patent Application Publication Dec. 18, 2003 Sheet 9 of 19 US 2003/0232890 A1 FIG. 14A FIG. 4B Total Distance Number of Movements 50 20 s w-- Sairie -- Saline d 500 -o-C05 -o-C05 2 400 d - s 3 soo 's 10 s s 200 s 100 Z 0 O 0 2 3 4 5 & 7 8 9 lo 0 1 2 3 4 5 s 7 8 9 10 Time (min) Tine (min) FIG. 4D Movement Time Number of Rears 40 Sali -a -Sale 10 -o-C105 -HSainte st 30 -o-C05 AaE 20 s s 8 3 to 2. O 0. O 2 3 4 5 - 6 8 9 IO 0 1 2 3 4 5 6 7 8 9 O Time (min) Time (min) FIG. 14E Number of Stereotyped Movements Time Spent Resting 50 -- Saline 50 -o-C105 4. O 230. to 0 1 2 3 4 5 6 7 8 9 0 0 1 2 3 4 S 6 8 9 O Time (min) - Time (min) Patent Application Publication Dec. 18, 2003 Sheet 10 of 19 US 2003/0232890 A1 FIG. 15A FIG. 15B Number of Movements Total Distance t ----sulfil -- contre S 500 --0-s-(+)-mphetamine --St-amphetamine. -- s 3. ) 300 . a 20 f 2 s s t 6 8 Tirne (min) Timc (min) FIG. 15C FIG. 15D Number of Rears Movement Time 50 ar -- Control -- Ili 340 -o-S-(+)-amphetamine -0-S-(+)-amphetamins e 30 - 5 20 g d to 0 1 2 3 4 5 6 8 s 10 Time (min) FIG. 5E FIG. 5F Number of Stereotyped Movements Time Spent Resting s 5 e -- Citro ar -- control -o-anphetamine v. 3 -o-S-(+)-amphetamire ex p 0. 's 30 i A. s 2 a. E 10 2 3 4 5 6 9 0. 2 4. 6 Tint (in) Time (min) Patent Application Publication Dec. 18, 2003 Sheet 11 of 19 US 2003/0232890 A1 Figure 16 12 2. 3. 10 > 2 8 d) - 6 M .2 4 is 2 - 5 g g H en r ca Figure 17 Patent Application Publication Dec. 18, 2003 Sheet 12 of 19 US 2003/0232890 A1 M 2 O CMO c5 itis 3 A -- san EO) C c e C C C C C N \o bf S ef. N - uope.I]uaouOO papalpad Patent Application Publication Dec. 18, 2003 Sheet 13 of 19 US 2003/0232890 A1 o vu O CN CO N vm vm (SL = Xeu) IIeoop.IOM Patent Application Publication Dec. 18, 2003 Sheet 14 of 19 US 2003/0232890 A1 600 500 400 3OO 2OO 1 OO O % -- veh 1.0 2.0 0.5 1.0 0.25 0.5 d-amph C 105 SN522 Dose (mg/kg) FIG. 20 Patent Application Publication Dec. 18, 2003 Sheet 15 of 19 US 2003/0232890 A1 500 234OOO OOO 10 O O 0.1 0.25 0.50 0.75 1.0 Dose of l-methanphetamine (mg/kg) FIG 21 Patent Application Publication Dec. 18, 2003 Sheet 16 of 19 US 2003/0232890 A1 -- Saline 60 -O- SN522 (0.25 mg/kg) -a- SN522 (0.5 mg/kg) 50 40 30 10 Trials FIG. 22 Patent Application Publication Dec. 18, 2003 Sheet 17 of 19 US 2003/0232890 A1 1200 -O- SN522 (0.25 mg/kg) -A-SN522 (0.5 mg/kg) 1000 -O- SN522 (2.5 mg/kg) -A- SN522 (5.0 mg/kg) 800 800 400 200 Time After injection (min) FIG. 23 1200 -O- d-amph (0.25 mg/kg) -A- d-amph (0.5 mg/kg) 1 1 O O -- d-Amph (2.5 mg/kg) 1000 -A-d-Amph (5.0 mg/kg) 900 800 700 600 500 400 300 200 100 is 9 & S. $ is 8 & Time After injection FIG. 24 Patent Application Publication Dec. 18, 2003 Sheet 18 of 19 US 2003/0232890 A1 30 min 24 hr Recall Time * P<0.05 vs. placebo (0 mg) F.G. 25 Patent Application Publication Dec. 18, 2003 Sheet 19 of 19 US 2003/0232890A1 Placebo C105 individual RAVLT Scores for Volunteers 0 21-49 Years Old o 60-72 Years Old FIG. 26 US 2003/0232890 A1 Dec. 18, 2003 METHODS FOR TREATING AN IMPAIRMENT IN 0006 Accordingly, methods and compositions that MEMORY CONSOLIDATION enhance long-term memory function and/or performance, or prophylactically (e.g., as a neuroprotective treatment) pre RELATED APPLICATIONS vent or slow degradation of long-term memory function and/or performance would be desirable. Similarly, methods 0001. This application is a continuation-in-part of U.S. and compositions for restoring long-term memory function application Ser. No. 10/139,606, filed May 2, 2002, which is and/or performance are needed. a continuation-in-part of U.S. application Ser. No. 10/003, 740 filed Oct. 31, 2001, which claims the benefit of U.S. 0007 Impairments in memory consolidation in a human Provisional Application No. 60/245,323 filed on Nov. 1, can occur in a number of conditions or diseases, Such as 2000 and claims priority to International Application PCT/ age-related memory loSS, Alzheimer's disease, Multiple US01/45793, filed Oct. 31, 2001, which designates the Sclerosis, brain injury, brain aneurysm, Stroke, Schizophre United States and was published in English. The teachings nia and epilepsy. Clinical management Strategies currently of the above applications are incorporated herein by refer provide minimal, if any, improvement in memory.
Load more

Recommended publications
  • MRO Manual Before 2004
    Note: This manual is essentially the same as the 1997 HHS Medical Review Officer (MRO) Manual except for changes related to the new Federal Custody and Control Form (CCF). The appendix has also been deleted since the new Federal Custody and Control Form is available as a separate file on the website. Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs for use with the new Federal Drug Testing Custody and Control Form (OMB Number 0930-0158, Exp Date: June 30, 2003) This manual applies to federal agency drug testing programs that come under Executive Order 12564 and the Department of Health and Human Services (HHS) Mandatory Guidelines. Table of Contents Chapter 1. The Medical Review Officer (MRO) ............................................................... 1 Chapter 2. Federal Drug Testing Custody and Control Form .......................................... 3 Chapter 3. The MRO Review Process ............................................................................ 3 A. Administrative Review of the CCF ........................................................................... 3 I. State Initiatives and Laws ....................................................................................... 15 Chapter 4. Specific Drug Class Issues .......................................................................... 15 A. Amphetamines ....................................................................................................... 15 B. Cocaine ................................................................................................................
    [Show full text]
  • Methamphetamine and Other Potentially Risky Sex-Enhancing Drugs
    METHAMPHETAMINE AND OTHER POTENTIALLY RISKY SEX-ENHANCING DRUGS A DISSERTATION SUBMITTED TO THE FACULTY OF THE AMERICAN ACADEMY OF CLINICAL SEXOLOGISTS AT MAIMONIDES UNIVERSITY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY BY DAVID MICHAEL FAWCETT ALFREDO EUGENIO TAULE' NORTH MIAMI BEACH, FLORIDA DECEMBER, 2004 DISSERTATION APPROVAL This dissertation submitted by David Michael Fawcett and Alfredo Eugenio Taule' has been read and approved by three faculty members of the American Academy of Clinical Sexologists at Maimonides University. The final copies have been examined by the Dissertation Committee and the signatures which appear here verify the fact that any necessary changes have been incorporated and the dissertation is now given the final approval with reference to content, form and mechanical accuracy. The dissertation is therefore accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Signature Date ______________________________ ______________ William Granzig, Ph.D., FAACS Advisor and Committee Chair ______________________________ _______________ John Achinapura, Ph.D. Committee Member ______________________________ _______________ James Walker, Ph.D. Committee Member ii ACKNOWLEDGEMENTS I dedicate this dissertation to my first born son Timothy who at the age of thirty-four after the terrorist attack in New York and Washington became a part of our proud military forces. At present he is a proud Airborne Ranger protecting our nation in a dangerous forward zone in the Sunni Triangle in Iraq. Timothy's resolve and courage as well as all of his accomplishments in such a short period of time have become a great source of inspiration for our family. My son has become my hero and he has made me aware of noble feelings like honor, loyalty, patriotism and commitment.
    [Show full text]
  • Concepts and Opinions About the Use of Stimulant Medications
    Journal of Child Psychology and Psychiatry 50:1-2 (2009), pp 180–193 doi:10.1111/j.1469-7610.2008.02062.x Psychopharmacology: concepts and opinions about the use of stimulant medications James M. Swanson and Nora D. Volkow This ‘perspective piece’ on the topic of psychophar- Many reviews have been published to summarize macology was requested to be opinion-driven and the plethora of studies that followed, including conceptual in nature, rather than a systematic influential early reviews in this journal (see Barkley, review or a state-of-the-science article. Recently we 1977) and from the European perspective by Taylor (Volkow & Swanson, 2008a) adopted a broad (1979) and in this journal by Bramble (2003). All approach to address multiple classes of psychotropic seem to reach about the same basic conclusions medication used to treat children (stimulants, anti- about the effects of AMP and MPH that were reported depressants, and anti-psychotics). We provided in these initial studies. Fifteen years ago these were examples from traditional clinical pharmacology to summarized by Swanson et al. (1993) in a ‘review of discuss their pharamacokinetic (PK) and pharma- reviews’ that suggested what should be expected codynamic (PD) properties, as well as examples from (e.g., short-term reduction in symptoms of ADHD modern positron emission tomography (PET) brain and associated features of opposition and aggres- imaging to characterize the time course of drug sion) and what should not be expected (long-term effects at the primary cellular sites of action in the benefits, absence of side effects, paradoxical re- brain (transporters, enzymes, and receptors).
    [Show full text]
  • WAC 246 -887 CHAPTER.Fm
    Chapter 246-887 Chapter 246-887 WAC PHARMACY—REGULATIONS IMPLEMENTING THE UNIFORM CONTROLLED SUBSTANCES ACT WAC 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 246-887-020 Uniform Controlled Substances Act. (Order 191B), recodified as § 246-887-070, filed 246-887-040 Designation of nonnarcotic stimulant drugs for purposes 8/30/91, effective 9/30/91. Statutory Authority: RCW of RCW 69.50.402 (1)(c). 69.50.201. WSR 89-17-023 (Order 226), § 360-36-260, 246-887-045 Prescribing, dispensing, or administering of Schedule II filed 8/8/89, effective 9/8/89; Order 138, § 360-36-260, nonnarcotic stimulants. filed 11/8/77.] Repealed by WSR 12-21-118, filed 246-887-080 Sodium pentobarbital registration disciplinary action. 10/23/12, effective 11/23/12. Statutory Authority: RCW 246-887-090 Authority to control. 69.41.080, 69.50.310, and 18.64.005. Later promulga- 246-887-100 Schedule I. tion, see chapter 246-886 WAC. 246-887-110 Adding MPPP to Schedule I. 246-887-220 Chemical capture programs. [Statutory Authority: RCW 246-887-120 Adding PEPAP to Schedule I. 69.50.320, 18.64.005. WSR 05-20-106, § 246-887-220, 246-887-130 Adding MDMA to Schedule I. filed 10/5/05, effective 11/8/05.] Repealed by WSR 15- 246-887-131 Adding Methcathinone to Schedule I. 12-020, filed 5/22/15, effective 6/22/15. Statutory 246-887-132 Adding Aminorex to Schedule I. Authority: RCW 18.64.005, 69.50.320, 69.41.080, and 246-887-133 Adding Alpha-ethyltryptamine to Schedule I.
    [Show full text]
  • DOCUMENT RESUME CO 005 692 Resource Book for Drug
    DOCUMENT RESUME ED 042 190 CO 005 692 TITLE Resource Book for Drug Abuse Education. INSTITUTION National Education Association, Washington, D.C.; National Inst. of Mental Health (DHEW), ChevyChase, Md. National Clearinghouse for Mental Health Infcrmation.; Public Health Service (DHEW) , Arlington, Va. PUB DATE Oct 69 NOTE 120p. AVAILABLE FRCM Superintendent of Documents, United States Government Printing Office, Washington, D.C. 20402 ($1.25 per copy) EDRS PRICE EDRS Price MF-$0.50 HC Not Available from EDRS. DESCRIPTORS Attitudes, Audiovisual Aids, Communication (Thought Transfer), *Drug Abuse, Drug Addiction, *Instructional Materials, Resource Guides, *Student Attitudes, Teaching Methods, *Teaching Techniques, *Workshops ABSTRACT This Resource Book contains summaries of factual information on drug abuse as well as techniques and suggestions that experienced drug educators have found helpful in communicating with young people who are thinking about drugs or have already experimented with them. An effort has been made to include papers by medical authorities and social scientists which reflect a range of views regarding drugs. The goal is the development of skills in the use of drug materials which will enable teachers to open up the kind of dialogue and discussion that is a prime requisite in influencing youth attitudes. A section on planning drug abuse education workshops is included. The book is divided into five parts: (1) teaching about drugs; (2) facts about drugs;(3) supplementary reports on drugs; (4) drug films; and (5)how to plan a drug abuse education workshop. Selected references are listed afrb end of the book. (KJ) Ell a ea a aa a0 0 * A a P 0 I 0 a 0 i f U SDEPARTMENT OF HEALTH, EDUCATION & WELFARE OFFICE OF EDUCATION THIS DOCUMENT HAS BEEN REPRODUCED EXACTLY AS RECEIVED FROM THE PERSON OR ORGANIZATION ORIGINATING IT POINTS Of VIEW OR OPINIONS STATED DO NOT NECESSARILY REPRESENT OFFICIAL OFFICE OF EDUCATION POSITION OR POLICY 0 0 National Clearinghouse for Menial Health Information RESOURCE BOOK FOR DRUG ABUSE EDUCATION 1! S.
    [Show full text]
  • EMERGING DRUG TRENDS – 2014 Special Research Report • Regional Organized Crime Information Center
    EMERGING DRUG TRENDS – 2014 Special Research Report • Regional Organized Crime Information Center Emerging Drug Trends Table of Contents Opioid Abuse .................................................... 2 By ROCIC Publications Specialist Jennifer Adkins Opiate Abuse .................................................... 7 © Regional Organized Crime Information Center Synthetic Cathinones ..................................... 13 ew drugs are emerging at an unprecedented rate as manufacturers Synthetic Cannabinoids ................................. 18 of “legal high” products use new chemicals to replace those that Phenethlyamines ............................................ 22 N Party Pills ...................................................27 are banned. These new chemicals take the place of heroin, morphine, and amphetamines. These drugs are highly accessible, touted as legal, Herbal Drugs ..............................................29 Sources of Information ...............................32 and perceived as safe. This Special Research Report was supported by Grant No. 2011-RS-CX-K007, awarded by the Bureau of Justice Assistance, Office of Justice Programs, U.S. However, despite the popularity in designer drugs and legal high Department of Justice. The Office of Justice Programs also coordinates the activi- ties of the Bureau of Justice Statistics, the National Institute of Justice, the Office of products, the abuse of heroin and prescription painkiller medication Juvenile Justice and Delinquency, and the Office for Victims of Crime.
    [Show full text]
  • 021303Orig1s005
    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 021303Orig1s005 Trade Name: ADDERALL XR Generic or Proper Dextroamphetamine Saccharate , Amphetamine Name: Aspartate Monohydrate Dextroamphetamine Sulfate Amphetamine Sulfate Sponsor: Shire Approval Date: 08/11/2004 Indication: ADDERALL XR™ is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). CENTER FOR DRUG EVALUATION AND RESEARCH 021303Orig1s005 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter X Other Action Letters X Labeling X REMS Summary Review X Officer/Employee List Office Director Memo Cross Discipline Team Leader Review Medical Review(s) X Chemistry Review(s) X Environmental Assessment Pharmacology Review(s) Statistical Review(s) X Microbiology / Virology Review(s) Clinical Pharmacology/Biopharmaceutics Review(s) X Other Reviews X Risk Assessment and Risk Mitigation Review(s) Proprietary Name Review(s) Administrative/Correspondence Document(s) X CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 021303Orig1s005 APPROVAL LETTER NDA 21-303/S-005 Page 2 69009) and was effective June 8, 2004. For additional information, consult the following guidance for industry: Regulatory Submissions in Electronic Format – Content of Labeling (February 2004). Pediatric Research Equity Act (PREA) All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for ages less than 6 years and deferring pediatric studies for ages 13 to 17 years for this application. Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required postmarketing study commitments.
    [Show full text]
  • Characterization of Enantiometric Composition and Impurity Profile Of
    Gdańsk University of Technology Faculty of Chemistry Department of Analytical Chemistry Ph.D thesis THE CHARACTERIZATION OF ENANTIOMERIC COMPOSITION AND IMPURITY PROFILE OF METHAMPHETAMINE AND ITS CHLORO-INTERMEDIATES SYNTHESIZED BY EMDE METHOD mgr inż. Justyna Małgorzata Płotka Supervisors: Prof. Marek Biziuk Ph.D Calum Morrison Gdańsk 2014 I would like to express my sincere gratitude to my advisors, Professor MAREK BIZIUK and Doctor CALUM MORRISON, for the continuous support of my Ph.D study and research, for their patience, motivation, enthusiasm, and immense knowledge. I would like to gratefully and sincerely thank Professor JACEK NAMIEŚNIK for his scientific advice and knowledge and many insightful discussions and suggestions. I am very grateful to Professor VASIL SIMEONOV for cooperation and advice during the project. Thanks to all of my FRIENDS from Department of Analytical Chemistry for spiritual support and creating a pleasant working atmosphere. I would like to thank my loved ones, MUM, DAD, SISTER, BROTHER, SISTER-IN-LAW, AND MY NEPHEWS who have supported me throughout entire process, both by keeping me harmonious and helping me putting pieces together. I will be grateful forever for your love. I would like to thank my husband ŁUKASZ for being with me in good and bad times, for his love and friendship, for support and patience. 2 TABLE OF CONTENTS ABSTRACT 6 LIST OF ABBREVIATIONS AND ACRONYMS 7 INTRODUCTION 12 I THEORETICAL PART 14 1. Amphetamine-type compounds as psychoactive stimulants 14 1.1. Methylamphetamine – abused drug of the early 21st century 16 1.1.1. History 16 1.1.2. Characterization 18 1.1.3.
    [Show full text]
  • Journal of Addictive Disorders
    JAD/2005 JOURNAL OF ADDICTIVE DISORDERS Methamphetamine: A review of the literature on methamphetamine to provide an informative overview of the history of methamphetamine, how it is produced and distributed, and the impact it has on the individual, families, neighborhoods, communities and local government. 1 ARTICLE Everyday we see it…on the news, in the newspaper, and perhaps in our neighborhoods. Methamphetamine has become a household word and has been exclaimed as a scourge on our nation that has reached epidemic proportions. The Office of Victims of Crimes reports “methamphetamine is the fastest growing drug threat and the most prevalent synthetic drug manufactured in the United States.” According to the 2000 National Household Survey on Drug Abuse, an estimated 8.8 million people, approximately four percent of the population, has tried methamphetamine at some time in their lives, (SAMSHA 2000). According to the World Health Organization, over 35 million people use methamphetamine or amphetamine on a regular basis and it is considered the second most widely abused illicit drug next to cannabis, (Rawson, Anglin, Ling, 2002). Methamphetamine has become a tremendous problem for families, communities and local governments. Of 500 law enforcement agencies in 45 states reported an 87% increase in methamphetamine-related arrests in the last three years, and 62% reported increases in laboratory seizures. Fifty-eight percent said methamphetamine was their largest drug problem. Seventy percent of counties reported increases in robberies and burglaries because of methamphetamine; 62% reported increases in domestic violence; 53% reported an increase in assaults; and 27% reported and increase in identity theft. Bill Hansell, President-elect of the National Association of Counties and Umatilla County resident reports that “Meth abuse in ruining lives and families and filling our jails,” (Zernike 2005).
    [Show full text]
  • DRUGS of ABUSE I 2011 EDITION: a DEA Resource Guide of Actual Abuse of a Substance Is Indicative That a Drug Has a Schedule I Potential for Abuse
    U.S. Department of Justice DrUg enforcement AdminiStration WWW.DEA.GOV Drugs of2011 Abuse Edition A DEA REsouRcE GuiDE II. Controlled Substances Act coNtRolliNG DRuGs oR othER The Assistant Secretary, by authority of the Secretary, compiles substANcEs thRouGh FoRmAl the information and transmits back to the DEA: a medical and schEDuliNG scientific evaluation regarding the drug or other substance, a recommendation as to whether the drug should be controlled, The Controlled Substances Act (CSA) places all substances and in what schedule it should be placed. which were in some manner regulated under existing federal The medical and scientific evaluations are binding on the DEA law into one of five schedules. This placement is based upon with respect to scientific and medical matters and form a part the substance’s medical use, potential for abuse, and safety or of the scheduling decision. dependence liability. The Act also provides a mechanism for substances to be controlled (added to or transferred between Once the DEA has received the scientific and medical schedules) or decontrolled (removed from control). The evaluation from HHS, the Administrator will evaluate all available procedure for these actions is found in Section 201 of the data and make a final decision whether to propose that a drug Act (21 U.S.C. § 811). or other substance should be removed or controlled and into which schedule it should be placed. Proceedings to add, delete, or change the schedule of a drug If a drug does not have a potential for abuse, it cannot be or other substance may be initiated by the Drug Enforcement controlled.
    [Show full text]
  • Pharmacokinetics of Adderall
    ESP Project Pharmacokinetics of Adderall Vivian Chow & Thukarasha Sivapatharajah Differential Equations, Section 00001 Professor Ivan T. Ivanov May 15 2015 Table of Contents Introduction 2 Theory behind Pharmacology 2 Adderall 4 Pharmacokinetics 6 Situation 1: Blood-Gut Pharmacokinetic Model Using Adderall 7 Situation 2: Contrasting Behaviours of Adderall IR and Adderall XR 11 Situation 3: Adderall’s Effect on a Rhesus Monkey 14 Situation 4: Administering Drugs every 4, 8 & 16 hours 16 Conclusion 19 Works Cited 20 Appendix A 21 Appendix B 23 1 Introduction Most drugs fall into the categories of stimulants, depressants, opiates and hallucinogens, where the drugs can be addictive, induce dependency and have different effects on the human body. Some examples of drugs are Tylenol and Aspirin, as well as Marijuana and Tobacco. In addition, pharmacologists help expand the medical field by studying drugs through examining the interactions between chemical substances and living organisms before making drugs available to the population. Hence, this project will model the pharmacokinetics of a drug by studying its dissipation and removal rates in the body. Theory behind Pharmacology Pharmacology is the science that deals with drugs, their properties, actions and effects in the body. It involves the sciences of pharmaceutics for the preparation of the drugs, therapeutics for using drugs to treat diseases and toxicosis for the various side-effects (Magoma). Pharmacology can be divided into five processes: 1. The pharmaceutical process of drugs – chemical synthesis, formulation and distribution of drugs. 2. The pharmacokinetic process – the time course of drug concentration in the body via absorption, distribution, biotransformation and excretion of the drug.
    [Show full text]
  • Focusing in on Adderall
    FOCUSING IN ON ADDERALL By Jared Geist FOOD & DRUG LAW Professor Neal Fortin 12-7-2007 Jared Geist Focusing in on Adderall 2 FOCUSING IN ON ADDERALL TABLE OF CONTENTS Introduction ..................................................................................................... 3 I. Background .................................................................................................. 4 A. The History of Adderall as a Prescription Drug ..................................... 4 B. Adderall Abuse ........................................................................................ 6 II. Investigating Adderall's Health Risks ....................................................... 8 A. Health Canada Bans Adderall ................................................................ 8 B. The FDA Investigation and cases of American Adderall-related death . 11 III. The Harm-Benefit Analysis ...................................................................... 13 A. The Case Against Adderall Use ............................................................... 14 B. The Case For Adderall Use (And Why it is Wrong) ................................ 17 IV. Where do we go from here? ...................................................................... 18 A. The Problems with the FDA's Drug Approval Process ........................... 19 B. A Plan of Action ...................................................................................... 20 Conclusion ......................................................................................................
    [Show full text]